DOW JONES23,170.37+516.51 2.28%
S&P 5002,715.12+55.71 2.09%
NASDAQ8,033.79+146.53 1.86%

Cantor Fitzgerald Upgrades CymaBay Therapeutics to Overweight, Raises Price Target to $5

Cantor Fitzgerald analyst Eliana Merle upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Neutral to Overweight and raises the price target from $2 to $5.

Benzinga · 03/13/2020 11:10

Cantor Fitzgerald analyst Eliana Merle upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Neutral to Overweight and raises the price target from $2 to $5.